Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Orphan drugs

FDA approves drug for genetic condition that affects 20 patients worldwide

The FDA has approved uridine triacetate (Xuriden) for the treatment of orotic acuduria, a condition caused by a deficient enzyme which prevents the body from synthesising uridine (molecular structure pictured), a necessary component of ribonucleic acid

Source: Jynto / Wikimedia Commons

The FDA has given the green light to uridine triacetate (Xuriden) for patients with orotic aciduria, a condition that prevents the body from making uridine (molecular structure pictured), a necessary component of ribonucleic acid

The US Food and Drug Administration (FDA) has approved uridine triacetate (Xuriden) for the treatment of orotic aciduria — a rare genetic hereditary metabolic disorder that affects just 20 patients worldwide. 

It is the first FDA -approved drug for this condition, caused by a defective or deficient enzyme that prevents the body from synthesizing uridine, which is a necessary component of ribonucleic acid. 

Patients with the condition have abnormal blood counts and urinary tract obstruction. They can also fail to thrive and face developmental delays. 

Uridine triacetate has been given FDA orphan drug status because of the rarity of the condition. The drug review was also fast-tracked by the FDA because it has the potential to offer major advances in treatment. 

The drug manufacturer, Wellstat Therapeutics Corporation, was also granted a FDA rare paediatric disease priority review voucher, which encourages the development of new drugs and biologics for the prevention and treatment of rare paediatric diseases. 

The decision follows the results of a six-week open label trial in four patients with the condition aged 3–19 years old, and a six-month trial extension. 

The results both at six weeks and six months revealed that the hematologic parameters were stable. No side effects were found for up to nine months. 

The European Medicines Agency (EMA) — the drugs’ safety watchdog for the European Union (EU) — said uridine triacetate does not currently have a central authorisation in the EU. “This medicine is also not currently under evaluation for marketing authorisation by the EMA and there is currently no orphan designation for uridine triacetate in hereditary orotic aciduria,” it said.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069307

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The FDA has approved uridine triacetate (Xuriden) for the treatment of orotic acuduria, a condition caused by a deficient enzyme which prevents the body from synthesising uridine (molecular structure pictured), a necessary component of ribonucleic acid

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.